For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260417:nRSQ9731Aa&default-theme=true
RNS Number : 9731A Seraphim Space Investment Trust PLC 17 April 2026
SERAPHIM SPACE INVESTMENT TRUST PLC
(the "Company")
Director Declaration
In accordance with the requirements of UK Listing Rule 6.4.9 (2) R, the
Company advises that it has been notified of the following change to
directorships of other publicly quoted companies held by a member of the
Board.
Angela Lane was appointed as a Non-Executive Director of BlackRock Smaller
Companies Trust plc ("BRSC"), with effect from 17 April 2026. She will also
serve as a member of BRSC's Audit, Nomination & Remuneration, and
Management Engagement Committees.
Angela was a Non-Executive Director of BlackRock Throgmorton Trust plc until
the completion of its combination with BRSC.
Enquiries
Seraphim Space Manager LLP (via SEC Newgate)
Mark Boggett, CEO / James Bruegger, CIO / Rob Desborough, GP
SEC Newgate (Communications advisers) seraphim@secnewgate.co.uk (mailto:seraphim@secnewgate.co.uk)
Clotilde Gros / George Esmond / Harry Handyside +44 (0) 20 3757 6767
Deutsche Numis (Joint Corporate Broker)
Nathan Brown / Vicki Paine +44 (0) 20 7545 8000
J.P. Morgan Cazenove (Joint Corporate Broker)
William Simmonds / Rupert Budge +44 (0) 20 3493 8000
Ocorian Administration (UK) Limited seraphimteam@ocorian.com (mailto:seraphimteam@ocorian.com)
Lorna Zimny +44 (0) 28 9078 5880
Notes to Editors
About Seraphim Space Investment Trust plc
Seraphim Space Investment Trust plc (the "Company") is the world's first
listed fund focused on SpaceTech. The Company seeks exposure predominantly to
early and growth stage private financed SpaceTech businesses that have the
potential to dominate globally and that are sector leaders with first mover
advantages in areas such as climate, communications, mobility and cyber
security.
The Company is listed on the Main Market of the London Stock Exchange.
Further information is available at: https://investors.seraphim.vc
(https://investors.seraphim.vc/) .
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END RDNEAELXFSSKEFA
Copyright 2019 Regulatory News Service, all rights reserved